Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ANNA HALPERN

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1952531790
CMS profile
704057
Location
SEATTLE, WA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$1,223.26

3 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $1,100.00 2
Food and Beverage $123.26 1

By paying entity

PY2023 · entire year · sorted by reported total

Paying entityAmountRecords
ABBVIE INC. $1,100.00 2
CTI BioPharma Corp. $123.26 1

Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ANNA HALPERN

NPI 1952531790 · CMS profile ID 704057

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

SEATTLE, WA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1952531790?year=2023&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ANNA HALPERN, NPI 1952531790, CMS profile ID 704057. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1952531790?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). ANNA HALPERN, NPI 1952531790, CMS profile ID 704057. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1952531790?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
ANNA HALPERN, NPI 1952531790, CMS profile ID 704057, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1952531790?year=2023&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

3 matching records · $1,223.26 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 3 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–3 of 3.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
CTI BioPharma Corp. $123.2612/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1039688035 CMS
ABBVIE INC. $550.0011/22/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997422785 CMS
ABBVIE INC. $550.0001/23/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997422783 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2020 $3,300.00 1
PY2021 $1,660.00 2
PY2022 $585.67 2
PY2023 $1,223.26 3
PY2024 $277.32 5
PY2025 $6,539.93 3

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $827,949.32 641
PY2024 Principal investigator $566,406.00 261
PY2023 Principal investigator $102,938.19 71
PY2022 Principal investigator $588,631.39 40
PY2021 Principal investigator $751,174.50 8
PY2020 Principal investigator $363,188.60 3
PY2019 Principal investigator $200.00 1

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

641 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Sumitomo Pharma America, Inc. $129,870.15 12/17/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618880
Principal investigator 1 PharmaEssentia USA Corporation $8,893.81 12/16/2025 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A22-301 No dispute reported 06/30/2026 1246830261
Principal investigator 1 PharmaEssentia USA Corporation $3,616.00 12/16/2025 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A22-301 No dispute reported 06/30/2026 1246830266
Principal investigator 1 Incyte Corporation $23,695.10 12/05/2025 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1240493036
Principal investigator 1 Incyte Corporation $2,751.00 12/05/2025 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1240493053
Principal investigator 1 Karyopharm Therapeutics Inc. $1,615.00 12/03/2025 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246661608
Principal investigator 1 Karyopharm Therapeutics Inc. $150.00 12/03/2025 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246661630
Principal investigator 1 Karyopharm Therapeutics Inc. $625.00 12/03/2025 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246661652
Principal investigator 1 Karyopharm Therapeutics Inc. $2,197.00 12/03/2025 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246661767
Principal investigator 1 Karyopharm Therapeutics Inc. $3,985.00 12/03/2025 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246661849
Principal investigator 1 Karyopharm Therapeutics Inc. $673.00 12/03/2025 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246661855
Principal investigator 1 Karyopharm Therapeutics Inc. $1,289.00 12/03/2025 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246661979
Principal investigator 1 Karyopharm Therapeutics Inc. $791.00 12/03/2025 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246662047
Principal investigator 1 Karyopharm Therapeutics Inc. $3,985.00 12/03/2025 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246662051
Principal investigator 1 Karyopharm Therapeutics Inc. $673.00 12/03/2025 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246662177
Principal investigator 1 Karyopharm Therapeutics Inc. $150.00 12/03/2025 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246662201
Principal investigator 1 Karyopharm Therapeutics Inc. $4,016.00 12/03/2025 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246662211
Principal investigator 1 Incyte Corporation $97.00 12/01/2025 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1240492999
Principal investigator 1 Incyte Corporation $22,140.00 12/01/2025 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1240493016
Principal investigator 1 Incyte Corporation $1,308.00 12/01/2025 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1240493024
Principal investigator 1 Incyte Corporation $6,850.00 12/01/2025 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1240493030
Principal investigator 1 Incyte Corporation $2,400.00 12/01/2025 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1240493040
Principal investigator 1 Incyte Corporation $23,800.00 12/01/2025 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1240493047
Principal investigator 1 Incyte Corporation $19,240.00 12/01/2025 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1240493058
Principal investigator 1 Incyte Corporation $288.00 12/01/2025 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1240493064
Principal investigator 1 Incyte Corporation $19,056.00 12/01/2025 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1240493096
Principal investigator 1 Incyte Corporation $14,379.00 12/01/2025 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1240493103
Principal investigator 1 Incyte Corporation $3,060.00 12/01/2025 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1240493113
Principal investigator 1 Incyte Corporation $2,223.77 12/01/2025 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1240493138
Principal investigator 1 PharmaEssentia USA Corporation $11,840.34 11/25/2025 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A22-301 No dispute reported 06/30/2026 1246830257
Principal investigator 1 Incyte Corporation $1,713.40 11/17/2025 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1240492992
Principal investigator 1 Incyte Corporation $3,569.00 11/17/2025 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1240493108
Principal investigator 1 Incyte Corporation $2,751.00 11/17/2025 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1240493145
Principal investigator 1 Sumitomo Pharma America, Inc. $16.20 11/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618790
Principal investigator 1 Sumitomo Pharma America, Inc. $16.20 11/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618795
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 11/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618799
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 11/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618803
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 11/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618806
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 11/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618812
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 11/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618815
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 11/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618819
Principal investigator 1 Sumitomo Pharma America, Inc. $0.50 11/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618822
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 11/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618826
Principal investigator 1 Sumitomo Pharma America, Inc. $0.50 11/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618830
Principal investigator 1 Sumitomo Pharma America, Inc. $16.20 11/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618835
Principal investigator 1 Sumitomo Pharma America, Inc. $16.20 11/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618839
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 11/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618843
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 11/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618847
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 11/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618851
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 11/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618855
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 11/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618859
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 11/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618863
Principal investigator 1 Sumitomo Pharma America, Inc. $0.50 11/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618867
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 11/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618871
Principal investigator 1 Sumitomo Pharma America, Inc. $0.50 11/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618876
Principal investigator 1 Incyte Corporation $3,317.00 10/20/2025 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1240493003
Principal investigator 1 Incyte Corporation $105.70 10/20/2025 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1240493009
Principal investigator 1 Incyte Corporation $3,569.00 10/20/2025 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1240493070
Principal investigator 1 Incyte Corporation $2,150.00 10/20/2025 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1240493078
Principal investigator 1 Incyte Corporation $2,150.00 10/20/2025 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1240493084
Principal investigator 1 Incyte Corporation $2,150.00 10/20/2025 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1240493089
Principal investigator 1 Incyte Corporation $2,751.00 10/20/2025 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1240493119
Principal investigator 1 Incyte Corporation $3,155.00 10/20/2025 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1240493126
Principal investigator 1 Incyte Corporation $3,155.00 10/20/2025 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1240493133
Principal investigator 1 PharmaEssentia USA Corporation $2,584.00 10/07/2025 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A22-301 No dispute reported 06/30/2026 1246830253
Principal investigator 1 PharmaEssentia USA Corporation $13,809.16 09/23/2025 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A22-301 No dispute reported 06/30/2026 1246830250
Principal investigator 1 Incyte Corporation $1,026.40 09/10/2025 Covered Recipient Teaching Hospital
Uw Medicine/Northwest Hospital
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1240497647
Principal investigator 1 Incyte Corporation $2,150.00 09/10/2025 Covered Recipient Teaching Hospital
Uw Medicine/Northwest Hospital
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1240497651
Principal investigator 1 Incyte Corporation $1,515.80 09/10/2025 Covered Recipient Teaching Hospital
Uw Medicine/Northwest Hospital
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1240497655
Principal investigator 1 Incyte Corporation $2,150.00 09/10/2025 Covered Recipient Teaching Hospital
Uw Medicine/Northwest Hospital
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1240497664
Principal investigator 1 Incyte Corporation $3,317.00 09/10/2025 Covered Recipient Teaching Hospital
Uw Medicine/Northwest Hospital
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1240497667
Principal investigator 1 Incyte Corporation $3,755.00 09/10/2025 Covered Recipient Teaching Hospital
Uw Medicine/Northwest Hospital
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1240497672
Principal investigator 1 Incyte Corporation $2,150.00 09/10/2025 Covered Recipient Teaching Hospital
Uw Medicine/Northwest Hospital
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1240497721
Principal investigator 1 Incyte Corporation $2,150.00 09/10/2025 Covered Recipient Teaching Hospital
Uw Medicine/Northwest Hospital
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1240497724
Principal investigator 1 Incyte Corporation $70.32 09/09/2025 Non-covered Recipient Entity
FRED HUTCHINSON CANCER CENTER
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1240536929
Principal investigator 1 Sumitomo Pharma America, Inc. $95.50 09/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618717
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 09/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618720
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 09/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618724
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 09/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618728
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 09/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618733
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 09/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618737
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 09/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618741
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 09/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618744
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 09/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618749
Principal investigator 1 Sumitomo Pharma America, Inc. $95.50 09/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618752
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 09/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618756
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 09/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618760
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 09/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618764
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 09/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618769
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 09/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618773
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 09/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618778
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 09/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618782
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 09/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618786
Principal investigator 1 Sumitomo Pharma America, Inc. $10,493.37 08/28/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618710
Principal investigator 1 Incyte Corporation $178.20 08/13/2025 Covered Recipient Teaching Hospital
Uw Medicine/Northwest Hospital
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1240497677
Principal investigator 1 Incyte Corporation $3,317.00 08/13/2025 Covered Recipient Teaching Hospital
Uw Medicine/Northwest Hospital
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1240497705
Principal investigator 1 Incyte Corporation $2,150.00 08/13/2025 Covered Recipient Teaching Hospital
Uw Medicine/Northwest Hospital
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1240497709
Principal investigator 1 Incyte Corporation $3,317.00 08/13/2025 Covered Recipient Teaching Hospital
Uw Medicine/Northwest Hospital
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1240497713
Principal investigator 1 Incyte Corporation $3,317.00 08/13/2025 Covered Recipient Teaching Hospital
Uw Medicine/Northwest Hospital
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1240497717
Principal investigator 1 Incyte Corporation $2,150.00 08/13/2025 Covered Recipient Teaching Hospital
Uw Medicine/Northwest Hospital
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1240497728
Principal investigator 1 Incyte Corporation $3,317.00 08/13/2025 Covered Recipient Teaching Hospital
Uw Medicine/Northwest Hospital
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1240497740
Principal investigator 1 Incyte Corporation $288.00 07/31/2025 Covered Recipient Teaching Hospital
Uw Medicine/Northwest Hospital
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1240497660
Principal investigator 1 Incyte Corporation $1,962.00 07/31/2025 Covered Recipient Teaching Hospital
Uw Medicine/Northwest Hospital
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1240497682
Principal investigator 1 Incyte Corporation $958.70 07/31/2025 Covered Recipient Teaching Hospital
Uw Medicine/Northwest Hospital
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1240497687
Principal investigator 1 PharmaEssentia USA Corporation $27,324.63 07/15/2025 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A22-301 No dispute reported 06/30/2026 1246830246
Principal investigator 1 Incyte Corporation $815.40 07/14/2025 Covered Recipient Teaching Hospital
Uw Medicine/Northwest Hospital
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1240497691
Principal investigator 1 Incyte Corporation $2,150.00 07/14/2025 Covered Recipient Teaching Hospital
Uw Medicine/Northwest Hospital
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1240497695
Principal investigator 1 Incyte Corporation $3,579.00 07/14/2025 Covered Recipient Teaching Hospital
Uw Medicine/Northwest Hospital
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1240497699
Principal investigator 1 Incyte Corporation $3,317.00 07/14/2025 Covered Recipient Teaching Hospital
Uw Medicine/Northwest Hospital
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1240497732
Principal investigator 1 Incyte Corporation $2,150.00 07/14/2025 Covered Recipient Teaching Hospital
Uw Medicine/Northwest Hospital
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1240497736
Principal investigator 1 Karyopharm Therapeutics Inc. $6,758.00 07/03/2025 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246662223
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617219
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617223
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617227
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617231
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617236
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617241
Principal investigator 1 Sumitomo Pharma America, Inc. $16.20 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617246
Principal investigator 1 Sumitomo Pharma America, Inc. $16.20 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617250
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617254
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617258
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617262
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617266
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617270
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617274
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617278
Principal investigator 1 Sumitomo Pharma America, Inc. $16.20 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617282
Principal investigator 1 Sumitomo Pharma America, Inc. $16.20 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617286
Principal investigator 1 Sumitomo Pharma America, Inc. $16.20 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617290
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617294
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617298
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617302
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617306
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617310
Principal investigator 1 Sumitomo Pharma America, Inc. $16.20 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617314
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617318
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617322
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617326
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617330
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617334
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617338
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617342
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617344
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617347
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617351
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617355
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617359
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617363
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617368
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617371
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617376
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617380
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617384
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617388
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617392
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617395
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617399
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617402
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617406
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617411
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617414
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617418
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617422
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617427
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617430
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617434
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617439
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617443
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617447
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617451
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617455
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617459
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617463
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617466
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617470
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617475
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617478
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617482
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617485
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617490
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617494
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617499
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617503
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617506
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617510
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617514
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617518
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617521
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617525
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617530
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617533
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617537
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617541
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617545
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617548
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617552
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617556
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617560
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617564
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617568
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617573
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617576
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617580
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617585
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617589
Principal investigator 1 Sumitomo Pharma America, Inc. $0.50 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617593
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617598
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617602
Principal investigator 1 Sumitomo Pharma America, Inc. $0.50 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617605
Principal investigator 1 Sumitomo Pharma America, Inc. $0.50 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617608
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617613
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617617
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617621
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617624
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617628
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617632
Principal investigator 1 Sumitomo Pharma America, Inc. $0.50 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617636
Principal investigator 1 Sumitomo Pharma America, Inc. $0.50 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617641
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617645
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617649
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617653
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617657
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617660
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617665
Principal investigator 1 Sumitomo Pharma America, Inc. $0.50 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617668
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617672
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617676
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617680
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617684
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617689
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617693
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617697
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617702
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617705
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617709
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617714
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617718
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617722
Principal investigator 1 Sumitomo Pharma America, Inc. $16.20 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617726
Principal investigator 1 Sumitomo Pharma America, Inc. $16.20 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617731
Principal investigator 1 Sumitomo Pharma America, Inc. $16.20 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617736
Principal investigator 1 Sumitomo Pharma America, Inc. $16.20 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617740
Principal investigator 1 Sumitomo Pharma America, Inc. $16.20 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617744
Principal investigator 1 Sumitomo Pharma America, Inc. $16.20 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617748
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617751
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617756
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617760
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617765
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617769
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617773
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617777
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617780
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617785
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617788
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617794
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617798
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617802
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617806
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617810
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617813
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617818
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617822
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617826
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617833
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617837
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617841
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617845
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617849
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617852
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617856
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617859
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617862
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617867
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617871
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617876
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617879
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617882
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617887
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617891
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617896
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617900
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617905
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617909
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617913
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617917
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617921
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617924
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617929
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617933
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617937
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617940
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617944
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617949
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617953
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617957
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617962
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617967
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617971
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617975
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617979
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617983
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617987
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617991
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617994
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617998
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618002
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618006
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618010
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618014
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618019
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618023
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618026
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618029
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618034
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618037
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618041
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618045
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618049
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618053
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618057
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618059
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618064
Principal investigator 1 Sumitomo Pharma America, Inc. $0.50 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618067
Principal investigator 1 Sumitomo Pharma America, Inc. $0.50 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618071
Principal investigator 1 Sumitomo Pharma America, Inc. $0.50 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618075
Principal investigator 1 Sumitomo Pharma America, Inc. $0.50 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618079
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618083
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618086
Principal investigator 1 Sumitomo Pharma America, Inc. $0.50 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618090
Principal investigator 1 Sumitomo Pharma America, Inc. $0.50 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618094
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618098
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618102
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618106
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618109
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618113
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618117
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618121
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618125
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618129
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618133
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618137
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618140
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618143
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618147
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618151
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618155
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618158
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618162
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618167
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618170
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618173
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618177
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618181
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618185
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618188
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618192
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618195
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618200
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618203
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618208
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618212
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618216
Principal investigator 1 Sumitomo Pharma America, Inc. $16.20 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618219
Principal investigator 1 Sumitomo Pharma America, Inc. $16.20 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618223
Principal investigator 1 Sumitomo Pharma America, Inc. $16.20 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618228
Principal investigator 1 Sumitomo Pharma America, Inc. $16.20 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618231
Principal investigator 1 Sumitomo Pharma America, Inc. $16.20 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618236
Principal investigator 1 Sumitomo Pharma America, Inc. $16.20 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618241
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618245
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618249
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618253
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618257
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618262
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618266
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618269
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618273
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618277
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618280
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618285
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618289
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618291
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618296
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618299
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618303
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618307
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618311
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618315
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618319
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618323
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618327
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618331
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618334
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618337
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618341
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618346
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618352
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618356
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618361
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618365
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618368
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618372
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618376
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618380
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618383
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618387
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618392
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618395
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618400
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618405
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618409
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618413
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618418
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618422
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618426
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618430
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618436
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618440
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618444
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618448
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618453
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618457
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618462
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618466
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618469
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618473
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618477
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618482
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618485
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618490
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618494
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618498
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618501
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618505
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618509
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618512
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618517
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618520
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618524
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618527
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618532
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618536
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618539
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618543
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618548
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618552
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618555
Principal investigator 1 Sumitomo Pharma America, Inc. $0.50 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618558
Principal investigator 1 Sumitomo Pharma America, Inc. $0.50 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618562
Principal investigator 1 Sumitomo Pharma America, Inc. $0.50 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618567
Principal investigator 1 Sumitomo Pharma America, Inc. $0.50 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618571
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618574
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618579
Principal investigator 1 Sumitomo Pharma America, Inc. $0.50 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618583
Principal investigator 1 Sumitomo Pharma America, Inc. $0.50 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618586
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618591
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618595
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618600
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618605
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618609
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618614
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618618
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618622
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618625
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618631
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618634
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618638
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618642
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618647
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618650
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618654
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618659
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618663
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618667
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618670
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618674
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618678
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618681
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618686
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618690
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618693
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618697
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618702
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176618706
Principal investigator 1 Sumitomo Pharma America, Inc. $544.38 06/27/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617211
Principal investigator 1 Sumitomo Pharma America, Inc. $1,622.00 06/27/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617215
Principal investigator 1 Incyte Corporation $3,579.00 06/20/2025 Non-covered Recipient Entity
FRED HUTCHINSON CANCER CENTER
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1240536815
Principal investigator 1 Incyte Corporation $3,317.00 06/20/2025 Non-covered Recipient Entity
FRED HUTCHINSON CANCER CENTER
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1240536820
Principal investigator 1 Incyte Corporation $3,579.00 06/20/2025 Non-covered Recipient Entity
FRED HUTCHINSON CANCER CENTER
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1240536824
Principal investigator 1 Incyte Corporation $2,150.00 06/20/2025 Non-covered Recipient Entity
FRED HUTCHINSON CANCER CENTER
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1240536830
Principal investigator 1 Incyte Corporation $3,317.00 06/20/2025 Non-covered Recipient Entity
FRED HUTCHINSON CANCER CENTER
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1240536834
Principal investigator 1 Incyte Corporation $2,150.00 06/20/2025 Non-covered Recipient Entity
FRED HUTCHINSON CANCER CENTER
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1240536851
Principal investigator 1 Incyte Corporation $2,150.00 06/20/2025 Non-covered Recipient Entity
FRED HUTCHINSON CANCER CENTER
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1240536921
Principal investigator 1 Incyte Corporation $2,150.00 06/20/2025 Non-covered Recipient Entity
FRED HUTCHINSON CANCER CENTER
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1240536926
Principal investigator 1 Sumitomo Pharma America, Inc. $19,911.91 06/12/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617207
Principal investigator 1 PharmaEssentia USA Corporation $2,664.00 06/10/2025 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A22-301 No dispute reported 06/30/2026 1246830240
Principal investigator 1 Incyte Corporation $1.50 06/09/2025 Non-covered Recipient Entity
FRED HUTCHINSON CANCER CENTER
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1240536754
Principal investigator 1 Incyte Corporation $35.16 06/09/2025 Non-covered Recipient Entity
FRED HUTCHINSON CANCER CENTER
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1240536782
Principal investigator 1 Incyte Corporation $61.26 06/09/2025 Non-covered Recipient Entity
FRED HUTCHINSON CANCER CENTER
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1240536786
Principal investigator 1 Incyte Corporation $10.21 06/09/2025 Non-covered Recipient Entity
FRED HUTCHINSON CANCER CENTER
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1240536790
Principal investigator 1 Incyte Corporation $48.75 06/09/2025 Non-covered Recipient Entity
FRED HUTCHINSON CANCER CENTER
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1240536794
Principal investigator 1 Incyte Corporation $121.11 06/09/2025 Non-covered Recipient Entity
FRED HUTCHINSON CANCER CENTER
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1240536802
Principal investigator 1 Incyte Corporation $20.42 06/09/2025 Non-covered Recipient Entity
FRED HUTCHINSON CANCER CENTER
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1240536807
Principal investigator 1 Incyte Corporation $30.63 06/09/2025 Non-covered Recipient Entity
FRED HUTCHINSON CANCER CENTER
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1240536811
Principal investigator 1 Incyte Corporation $123.36 06/09/2025 Non-covered Recipient Entity
FRED HUTCHINSON CANCER CENTER
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1240536892
Principal investigator 1 Incyte Corporation $61.26 06/09/2025 Non-covered Recipient Entity
FRED HUTCHINSON CANCER CENTER
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1240536904
Principal investigator 1 Incyte Corporation $23,800.00 06/04/2025 Non-covered Recipient Entity
FRED HUTCHINSON CANCER CENTER
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1240536847
Principal investigator 1 Incyte Corporation $9,944.74 06/04/2025 Non-covered Recipient Entity
FRED HUTCHINSON CANCER CENTER
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1240536864
Principal investigator 1 Incyte Corporation $19,056.00 06/04/2025 Non-covered Recipient Entity
FRED HUTCHINSON CANCER CENTER
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1240536870
Principal investigator 1 Incyte Corporation $5,917.46 06/04/2025 Non-covered Recipient Entity
FRED HUTCHINSON CANCER CENTER
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1240536900
Principal investigator 1 Incyte Corporation $3,299.00 05/07/2025 Non-covered Recipient Entity
FRED HUTCHINSON CANCER CENTER
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1240536838
Principal investigator 1 Incyte Corporation $4,868.00 05/07/2025 Non-covered Recipient Entity
FRED HUTCHINSON CANCER CENTER
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1240536842
Principal investigator 1 Incyte Corporation $2,150.00 05/07/2025 Non-covered Recipient Entity
FRED HUTCHINSON CANCER CENTER
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1240536857
Principal investigator 1 Incyte Corporation $2,150.00 05/07/2025 Non-covered Recipient Entity
FRED HUTCHINSON CANCER CENTER
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1240536860
Principal investigator 1 Incyte Corporation $3,755.00 05/07/2025 Non-covered Recipient Entity
FRED HUTCHINSON CANCER CENTER
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1240536876
Principal investigator 1 Incyte Corporation $5,341.00 05/07/2025 Non-covered Recipient Entity
FRED HUTCHINSON CANCER CENTER
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1240536879
Principal investigator 1 Incyte Corporation $2,150.00 05/07/2025 Non-covered Recipient Entity
FRED HUTCHINSON CANCER CENTER
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1240536883
Principal investigator 1 Incyte Corporation $2,150.00 05/07/2025 Non-covered Recipient Entity
FRED HUTCHINSON CANCER CENTER
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1240536887
Principal investigator 1 Incyte Corporation $5,341.00 05/07/2025 Non-covered Recipient Entity
FRED HUTCHINSON CANCER CENTER
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1240536909
Principal investigator 1 Incyte Corporation $5,341.00 05/07/2025 Non-covered Recipient Entity
FRED HUTCHINSON CANCER CENTER
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1240536913
Principal investigator 1 Incyte Corporation $4,868.00 05/07/2025 Non-covered Recipient Entity
FRED HUTCHINSON CANCER CENTER
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1240536917
Principal investigator 1 Karyopharm Therapeutics Inc. $105.00 05/05/2025 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246661568
Principal investigator 1 Karyopharm Therapeutics Inc. $105.00 05/05/2025 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246661576
Principal investigator 1 Karyopharm Therapeutics Inc. $105.00 05/05/2025 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246661612
Principal investigator 1 Karyopharm Therapeutics Inc. $105.00 05/05/2025 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246661622
Principal investigator 1 Karyopharm Therapeutics Inc. $105.00 05/05/2025 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246661664
Principal investigator 1 Karyopharm Therapeutics Inc. $105.00 05/05/2025 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246661670
Principal investigator 1 Karyopharm Therapeutics Inc. $105.00 05/05/2025 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246661684
Principal investigator 1 Karyopharm Therapeutics Inc. $750.00 05/05/2025 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246661715
Principal investigator 1 Karyopharm Therapeutics Inc. $105.00 05/05/2025 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246661737
Principal investigator 1 Karyopharm Therapeutics Inc. $105.00 05/05/2025 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246661751
Principal investigator 1 Karyopharm Therapeutics Inc. $105.00 05/05/2025 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246661753
Principal investigator 1 Karyopharm Therapeutics Inc. $105.00 05/05/2025 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246661761
Principal investigator 1 Karyopharm Therapeutics Inc. $105.00 05/05/2025 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246661765
Principal investigator 1 Karyopharm Therapeutics Inc. $105.00 05/05/2025 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246661789
Principal investigator 1 Karyopharm Therapeutics Inc. $105.00 05/05/2025 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246661803
Principal investigator 1 Karyopharm Therapeutics Inc. $387.00 05/05/2025 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246661837
Principal investigator 1 Karyopharm Therapeutics Inc. $387.00 05/05/2025 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246661839
Principal investigator 1 Karyopharm Therapeutics Inc. $105.00 05/05/2025 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246661841
Principal investigator 1 Karyopharm Therapeutics Inc. $105.00 05/05/2025 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246661863
Principal investigator 1 Karyopharm Therapeutics Inc. $387.00 05/05/2025 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246661865
Principal investigator 1 Karyopharm Therapeutics Inc. $105.00 05/05/2025 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246661879
Principal investigator 1 Karyopharm Therapeutics Inc. $105.00 05/05/2025 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246661885
Principal investigator 1 Karyopharm Therapeutics Inc. $105.00 05/05/2025 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246661923
Principal investigator 1 Karyopharm Therapeutics Inc. $105.00 05/05/2025 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246661925
Principal investigator 1 Karyopharm Therapeutics Inc. $387.00 05/05/2025 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246661937
Principal investigator 1 Karyopharm Therapeutics Inc. $105.00 05/05/2025 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246661943
Principal investigator 1 Karyopharm Therapeutics Inc. $105.00 05/05/2025 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246661967
Principal investigator 1 Karyopharm Therapeutics Inc. $750.00 05/05/2025 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246661981
Principal investigator 1 Karyopharm Therapeutics Inc. $105.00 05/05/2025 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246661987
Principal investigator 1 Karyopharm Therapeutics Inc. $105.00 05/05/2025 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246662013
Principal investigator 1 Karyopharm Therapeutics Inc. $105.00 05/05/2025 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246662019
Principal investigator 1 Karyopharm Therapeutics Inc. $105.00 05/05/2025 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246662029
Principal investigator 1 Karyopharm Therapeutics Inc. $105.00 05/05/2025 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246662033
Principal investigator 1 Karyopharm Therapeutics Inc. $387.00 05/05/2025 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246662045
Principal investigator 1 Karyopharm Therapeutics Inc. $387.00 05/05/2025 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246662049
Principal investigator 1 Karyopharm Therapeutics Inc. $387.00 05/05/2025 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246662055
Principal investigator 1 Karyopharm Therapeutics Inc. $105.00 05/05/2025 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246662117
Principal investigator 1 Karyopharm Therapeutics Inc. $105.00 05/05/2025 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246662123
Principal investigator 1 Karyopharm Therapeutics Inc. $105.00 05/05/2025 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246662127
Principal investigator 1 Karyopharm Therapeutics Inc. $975.00 05/05/2025 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246662135
Principal investigator 1 Karyopharm Therapeutics Inc. $105.00 05/05/2025 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246662155
Principal investigator 1 Karyopharm Therapeutics Inc. $105.00 05/05/2025 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246662173
Principal investigator 1 Karyopharm Therapeutics Inc. $105.00 05/05/2025 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246662225
Principal investigator 1 Karyopharm Therapeutics Inc. $105.00 05/05/2025 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246662233
Principal investigator 1 PharmaEssentia USA Corporation $59,970.45 04/15/2025 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A22-301 No dispute reported 06/30/2026 1246830235
Principal investigator 1 Incyte Corporation $1.00 04/08/2025 Non-covered Recipient Entity
FRED HUTCHINSON CANCER CENTER
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1240536758
Principal investigator 1 Incyte Corporation $30.63 04/08/2025 Non-covered Recipient Entity
FRED HUTCHINSON CANCER CENTER
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1240536762
Principal investigator 1 Incyte Corporation $77.60 04/08/2025 Non-covered Recipient Entity
FRED HUTCHINSON CANCER CENTER
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1240536766
Principal investigator 1 Incyte Corporation $175.80 04/08/2025 Non-covered Recipient Entity
FRED HUTCHINSON CANCER CENTER
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1240536769
Principal investigator 1 Incyte Corporation $8.45 04/08/2025 Non-covered Recipient Entity
FRED HUTCHINSON CANCER CENTER
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1240536774
Principal investigator 1 Incyte Corporation $121.11 04/08/2025 Non-covered Recipient Entity
FRED HUTCHINSON CANCER CENTER
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1240536778
Principal investigator 1 Incyte Corporation $116.40 04/08/2025 Non-covered Recipient Entity
FRED HUTCHINSON CANCER CENTER
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1240536798
Principal investigator 1 Incyte Corporation $18.50 04/08/2025 Non-covered Recipient Entity
FRED HUTCHINSON CANCER CENTER
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1240536895
Principal investigator 1 Incyte Corporation $13,284.00 04/07/2025 Non-covered Recipient Entity
FRED HUTCHINSON CANCER CENTER
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1240536872
Principal investigator 1 Karyopharm Therapeutics Inc. $105.00 04/07/2025 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246661566
Principal investigator 1 Karyopharm Therapeutics Inc. $105.00 04/07/2025 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246661578
Principal investigator 1 Karyopharm Therapeutics Inc. $105.00 04/07/2025 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246661606
Principal investigator 1 Karyopharm Therapeutics Inc. $387.00 04/07/2025 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246661614
Principal investigator 1 Karyopharm Therapeutics Inc. $105.00 04/07/2025 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246661620
Principal investigator 1 Karyopharm Therapeutics Inc. $387.00 04/07/2025 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246661694
Principal investigator 1 Karyopharm Therapeutics Inc. $105.00 04/07/2025 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246661699
Principal investigator 1 Karyopharm Therapeutics Inc. $387.00 04/07/2025 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246661707
Principal investigator 1 Karyopharm Therapeutics Inc. $387.00 04/07/2025 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246661895
Principal investigator 1 Karyopharm Therapeutics Inc. $105.00 04/07/2025 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246661903
Principal investigator 1 Karyopharm Therapeutics Inc. $105.00 04/07/2025 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246661907
Principal investigator 1 Karyopharm Therapeutics Inc. $387.00 04/07/2025 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246661915
Principal investigator 1 Karyopharm Therapeutics Inc. $105.00 04/07/2025 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246661977
Principal investigator 1 Karyopharm Therapeutics Inc. $105.00 04/07/2025 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246662011
Principal investigator 1 Karyopharm Therapeutics Inc. $1,300.00 04/07/2025 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246662071
Principal investigator 1 Karyopharm Therapeutics Inc. $387.00 04/07/2025 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246662085
Principal investigator 1 Karyopharm Therapeutics Inc. $105.00 04/07/2025 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246662115
Principal investigator 1 Karyopharm Therapeutics Inc. $105.00 04/07/2025 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246662157
Principal investigator 1 Karyopharm Therapeutics Inc. $387.00 04/07/2025 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246662191
Principal investigator 1 Sumitomo Pharma America, Inc. $6,878.32 04/03/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617203
Principal investigator 1 Sumitomo Pharma America, Inc. $11,443.00 03/20/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176617199
Principal investigator 1 Incyte Corporation $335.00 03/12/2025 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1240492912
Principal investigator 1 Incyte Corporation $5,341.00 03/12/2025 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1240492917
Principal investigator 1 Incyte Corporation $3,517.20 03/12/2025 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1240492961
Principal investigator 1 PharmaEssentia USA Corporation $23,147.00 03/11/2025 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A22-301 No dispute reported 06/30/2026 1246830232
Principal investigator 1 Incyte Corporation $77.60 03/10/2025 Non-covered Recipient Entity
FRED HUTCHINSON CANCER CENTER
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1240536725
Principal investigator 1 Incyte Corporation $88.08 03/10/2025 Non-covered Recipient Entity
FRED HUTCHINSON CANCER CENTER
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1240536729
Principal investigator 1 Incyte Corporation $246.72 03/10/2025 Non-covered Recipient Entity
FRED HUTCHINSON CANCER CENTER
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1240536733
Principal investigator 1 Incyte Corporation $20.42 03/10/2025 Non-covered Recipient Entity
FRED HUTCHINSON CANCER CENTER
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1240536737
Principal investigator 1 Incyte Corporation $20.42 03/10/2025 Non-covered Recipient Entity
FRED HUTCHINSON CANCER CENTER
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1240536740
Principal investigator 1 Incyte Corporation $122.52 03/10/2025 Non-covered Recipient Entity
FRED HUTCHINSON CANCER CENTER
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1240536745
Principal investigator 1 Incyte Corporation $77.60 03/10/2025 Non-covered Recipient Entity
FRED HUTCHINSON CANCER CENTER
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1240536749
Principal investigator 1 Karyopharm Therapeutics Inc. $6,758.00 03/06/2025 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246662081
Principal investigator 1 Incyte Corporation $1,020.00 02/21/2025 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1240492803
Principal investigator 1 Incyte Corporation $192.00 02/21/2025 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1240492830
Principal investigator 1 Incyte Corporation $1,853.00 02/21/2025 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1240492858
Principal investigator 1 Incyte Corporation $867.00 02/21/2025 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1240492932
Principal investigator 1 Karyopharm Therapeutics Inc. $97.00 02/12/2025 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246662149
Principal investigator 1 PharmaEssentia USA Corporation $48,657.60 02/05/2025 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A22-301 No dispute reported 06/30/2026 1246828693
Principal investigator 1 Incyte Corporation $586.00 01/31/2025 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1240492809
Principal investigator 1 Incyte Corporation $109.00 01/31/2025 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1240492816
Principal investigator 1 Incyte Corporation $141.00 01/31/2025 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1240492841
Principal investigator 1 Incyte Corporation $8.00 01/31/2025 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1240492847
Principal investigator 1 Incyte Corporation $8.00 01/31/2025 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1240492852
Principal investigator 1 Incyte Corporation $513.00 01/31/2025 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1240492863
Principal investigator 1 Incyte Corporation $3,121.30 01/31/2025 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1240492869
Principal investigator 1 Incyte Corporation $46.00 01/31/2025 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1240492876
Principal investigator 1 Incyte Corporation $141.00 01/31/2025 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1240492883
Principal investigator 1 Incyte Corporation $141.00 01/31/2025 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1240492890
Principal investigator 1 Incyte Corporation $549.00 01/31/2025 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1240492897
Principal investigator 1 Incyte Corporation $270.00 01/31/2025 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1240492901
Principal investigator 1 Incyte Corporation $981.00 01/31/2025 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1240492906
Principal investigator 1 Incyte Corporation $549.00 01/31/2025 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1240492922
Principal investigator 1 Incyte Corporation $152.00 01/31/2025 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1240492943
Principal investigator 1 Incyte Corporation $41.00 01/31/2025 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1240492949
Principal investigator 1 Incyte Corporation $141.00 01/31/2025 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1240492968
Principal investigator 1 Incyte Corporation $141.00 01/31/2025 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1240492972
Principal investigator 1 Incyte Corporation $141.00 01/31/2025 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1240492978
Principal investigator 1 Incyte Corporation $141.00 01/31/2025 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1240492986
Principal investigator 1 Incyte Corporation $301.00 01/10/2025 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1240492786
Principal investigator 1 Incyte Corporation $288.00 01/10/2025 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1240492791
Principal investigator 1 Incyte Corporation $1,020.00 01/10/2025 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1240492797
Principal investigator 1 Incyte Corporation $673.00 01/10/2025 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1240492823
Principal investigator 1 Incyte Corporation $4,251.00 01/10/2025 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1240492835
Principal investigator 1 Incyte Corporation $1,200.00 01/10/2025 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1240492928
Principal investigator 1 Incyte Corporation $568.00 01/10/2025 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1240492936
Principal investigator 1 Incyte Corporation $867.00 01/10/2025 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1240492955